These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1025631)

  • 1. The maximum allowable cost regulations and pharmaceutical research and development.
    Dickens PF
    Res Stat Note; 1976 Mar; (2):1-4. PubMed ID: 1025631
    [No Abstract]   [Full Text] [Related]  

  • 2. Position statement: On DHEW proposed rule making on maximum allowable cost for drugs.
    Challoner DR; Levine RJ
    Clin Res; 1975 Dec; 23(5):290. PubMed ID: 10325172
    [No Abstract]   [Full Text] [Related]  

  • 3. Maximum allowable cost for drugs.
    Hosp Formul; 1975 Mar; 10(3):116, 119-20. PubMed ID: 10237830
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic consequences of the maximum allowable cost program to the entire profession of pharmacy.
    Paul SH
    Med Mark Media; 1979 Aug; 14(8):19-26. PubMed ID: 10243270
    [No Abstract]   [Full Text] [Related]  

  • 5. View from the Nation's Capital.
    Freishtat HW
    J Clin Psychopharmacol; 1985 Apr; 5(2):117-9. PubMed ID: 3988970
    [No Abstract]   [Full Text] [Related]  

  • 6. A note on the gentle art of cost prediction: HEW computer model generates cost estimates for national health insurance plans.
    Lawrence SV
    Forum Med; 1979 May; 2(5):358-9. PubMed ID: 10241717
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotech and pharma face more costly clinical trials.
    Brower V
    Nat Biotechnol; 1998 Aug; 16(8):714. PubMed ID: 9702762
    [No Abstract]   [Full Text] [Related]  

  • 8. Reimbursement of drug cost-medical assistance program.
    Hosp Formul; 1975 Mar; 10(3):120, 122, 142. PubMed ID: 10297178
    [No Abstract]   [Full Text] [Related]  

  • 9. Key trend--1979: a year of price controls and cost containment.
    Szalanski A
    MPS; 1979 Feb; 10(2):1, 35-6. PubMed ID: 10240202
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost/success projections for US biodefense countermeasure development.
    Matheny J; Mair M; Smith B
    Nat Biotechnol; 2008 Sep; 26(9):981-3. PubMed ID: 18779804
    [No Abstract]   [Full Text] [Related]  

  • 11. Reimbursement on a reasonable cost related basis for skilled nursing and intermediate care facility services; supplemental statement of basis and purpose of regulations.
    Fed Regist; 1978 Feb; 43(25):4861-4. PubMed ID: 10306557
    [No Abstract]   [Full Text] [Related]  

  • 12. Maximum liability health insurance. The administration's national health insurance plan: a reassessment.
    Policy Anal; 1975; 1(2):289-329. PubMed ID: 1235884
    [No Abstract]   [Full Text] [Related]  

  • 13. "Maximum allowable cost" effective date delayed.
    Employee Benefit Plan Rev; 1976 Jun; 30(12):12, 14. PubMed ID: 1037550
    [No Abstract]   [Full Text] [Related]  

  • 14. Abolition of Pharmaceutical Reimbursement Advisory Committee: final regulation.
    Fed Regist; 1978 Aug; 43(154):35310-1. PubMed ID: 10297140
    [No Abstract]   [Full Text] [Related]  

  • 15. IMS updates HMM's pharmacy indexes.
    Doyle JJ
    Hosp Mater Manage; 1991 Jan; 16(1):19-22. PubMed ID: 10170632
    [No Abstract]   [Full Text] [Related]  

  • 16. New federal guidelines: a green light from government.
    Gosselin RA
    Hosp Formul; 1978 Jul; 13(7):546-9. PubMed ID: 10308293
    [No Abstract]   [Full Text] [Related]  

  • 17. HEW seeks labor, industry support for HMO's.
    Trustee; 1978 May; 31(5):57, 60. PubMed ID: 10307836
    [No Abstract]   [Full Text] [Related]  

  • 18. The pharmaceutical industry -- will Canada become a major research centre?
    Gray C
    Can Med Assoc J; 1981 Apr; 124(7):910, 914-5, 918 concl. PubMed ID: 7214290
    [No Abstract]   [Full Text] [Related]  

  • 19. Biomedical policy. NIH wins an exemption from HHS peer-review overhaul.
    Marshall E
    Science; 2001 Aug; 293(5533):1234. PubMed ID: 11509695
    [No Abstract]   [Full Text] [Related]  

  • 20. AIDS drugs & the pharmaceutical industry: a need for reform.
    Griffin MT
    Am J Law Med; 1991; 17(4):363-410. PubMed ID: 1812767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.